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Abstract
Background: Hepatitis C virus (HCV), either alone or in combination with Human Immunodeficiency virus (HIV),
constitutes a major public health concern. This study was conducted to describe the prevalence and risk factors for
HCV infection in people with and without HIV infection.
Methods: Blood samples and data on socio-demographic and risk factors for HCV infection were collected from
consecutive 400 HIV- positive and 400 HIV- negative individuals attending HIV testing centers in Hawassa city, from
October to December, 2008. All sera were tested for antibody to HCV infection (anti-HCV) using enzyme linked
immunosorbent assay (ELISA). Sera positive for anti-HCV were further tested for viral ribonucleic acid (RNA) levels
using real-time polymerase chain reaction.
Results: The rate of anti-HCV positivity was 10.5% in the HIV- infected individuals compared with 6% in the HIV
negative group (p = 0.002). HCV-RNA was detected in 9.1% of anti-HCV positive samples and rates were
comparable between HIV- infected and HIV- non-infected individuals. There was no significant difference in odds
of HCV infection in participants with and without HCV risk factors in either HIV sero-group.
Conclusion: HIV infected individuals had significantly higher rate of anti-HCV although most of them showed no
evidence of viraemia. Hence, while priority should be given for HIV infected patients, testing those with anti-HCV
for HCV-RNA remains important.
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Introduction
Hepatitis C virus (HCV) represents a major public
health burden in both industrialized and developing
countries. The prevalence of HCV infection is esti-
mated to be 2.2-3.0% (130-170 million people) world-
wide [1]. Region-specific estimates range from < 1.0%
in Northern Europe to > 2.9% in Northern Africa, with
the highest prevalence (15%-20%) reported in Egypt
[2]. About 15 to 20% of HCV infections progress to
potentially serious cirrhosis and end-stage liver disease
[3]. Due to shared mode of transmission, co-infection
of HCV and human immunodeficiency virus (HIV) has
become a growing public health concern. Among the
estimated 40 million individuals infected with HIV
worldwide, about 4-5 million are chronically infected
with HCV [4]. Prevalence and mode of transmission of
each of the two viral infections are the main determi-
nants of co-infection rate, and vary according to the
geographic region. For instance, co-infection is high in
patients that acquire the viruses through parenteral
routes compared with those infected through sexual
route [5].
In Ethiopia, a previous population-based survey had
reported a moderate prevalence (2%) of HCV infection
[6]. However, information is scarce regarding the rate of
HIV-HCV co-infection in our setting where HIV is pre-
valent. This study was conducted to describe the preva-
lence and risk factors for HCV infection in people with
and without HIV infection.
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Methods
A sero-prevalence study of HCV was conducted in peo-
ple with and without HIV infection attending HIV test-
ing centers (Hawassa Referral Hospital, Hawassa Health
Centre, Organization for Social Services for AIDS
(OSSA), and Beth-Zeta Hospital) from October to
December, 2008. These centers are located in Hawassa,
the capital city of the Southern Nations, Nationalities
and Peoples’ Regional State and one of the administra-
tive regions in Ethiopia. The centers provide voluntary
HIV counseling and testing services using two
approaches: a client-initiated approach to serve people
seeking to know their HIV status, and a provider-
initiated approach which enables health care provider
offer targeted medical services. Clients who are tested
HIV positive are usually referred to the Hawassa Refer-
ral Hospital. Clinical and immunological assessments
(CD4+ T cell count) at enrollment and at six-monthly
follow-up visits identify those who are eligible for anti-
retroviral therapy (ART). Those receiving ART monitor
their disease status on a regular basis. Services including
HIV counselling and testing, clinical and immunological
assessments as well as ART are provided free of charge.
In this study, consecutive HIV-positive individuals
who were at their first enrollment at the ART clinic as
well as those who had been receiving ART for at least
six months were recruited prospectively. Consecutive
clients, who were tested HIV negative at any of the cen-
ters during the study period, were recruited for com-
parative purposes. The sample size was estimated using
HCV prevalence rates of 4.5% and 0.8% in HIV-positive
and HIV-negative subjects, respectively [7]. With 95%
level of confidence and 80% power of the study, the
required sample size would be 800 (400 individuals in
each HIV sero-group). In both HIV sero-groups, only
individuals aged 15 years and above were included.
Among HIV-positive clients, those found with a CD4+
T cell counts below 50 cells/mm3 were excluded from
the study due to the unreliability of HCV serological
tests in a state of severe immunosuppression [8].
Counsellor nurses interviewed the study subjects using
structured questionnaires on socio-demographic charac-
teristics and risk factors of HCV infection such as his-
tory of traditional and modern medical practices, sexual
practices, history of sexual transmitted infections (STIs),
liver disease, and family history of liver disease. Remain-
ing sera left from HIV testing and CD4+ T cell mea-
surement were stored at -80°C for the purpose of HCV
testing. All sera were screened at the Hawassa Referral
Hospital laboratory for HCV antibody (anti-HCV) using
Enzyme Linked Immunosorbent Assay (ELISA)
(HUMAN anti-HCV ELISA, Germany). Sera found to be
positive for anti-HCV were transferred in cold boxes to
the International Clinical Laboratories in Addis Ababa
where testing for viral ribonucleic acid (RNA) using
real-time polymerase chain reaction (PCR) (Abbott Real-
Time™ HCV) was performed. According to the manu-
facturer’s guidelines, the real-time PCR test has
detection sensitivity of a viral load as low as 12 IU/ml of
serum. All samples were tested in accordance with the
manufacturer’s instructions and in duplicates to ensure
reproducibility. Despite the possibility that the ELISA
test introduces false positive result, we interpreted a
positive anti-HCV test as HCV-exposure. Presence of
HCV-RNA indicates active viral replication.
Data entry and analysis were performed using SPSS
Version-16. Descriptive summary was presented in
terms of mean, range, and proportions depending on
the scale of the variable. Pearson’s Chi-square test was
used to assess differences in proportion of anti-HCV
marker between HIV-infected and HIV-non-infected
individuals. The strength of association between HCV
status and risk factors was measured by calculating odds
ratios. A given statistical test was reported significant
whenever it resulted in a p-value < 0.05.
The study was approved by the Ethics Committees of
Aklilu Lemma Institute of Pathobiology, Addis Ababa Uni-
versity and the College of Medicine and Health Sciences,
Hawassa University. All participants gave informed written
consent, and doctors managed HCV-positive cases.
Results
Of the 402 HIV-positive and 404 HIV-negative indivi-
duals approached during the study period, 2 HIV-posi-
tive and 4 HIV-negative participants were excluded due
to insufficient blood volume and refusal, respectively.
The majority (94.7%) of HIV-infected participants were
urban dwellers and married (48%) (Table 1). The mean
age of HIV-infected participants was 31.7 years (range
18-70 years; SD 8.4) compared with 26.6 years (range
16-62 years; SD 7.3) in HIV- non-infected clients. The
male to female ratio was 0.6:1 in HIV-positive and 0.9:1
in HIV-negative clients. Two-hundred (50%) HIV-
infected participants were receiving ART.
The prevalence of anti-HCV in HIV-positive indivi-
duals was 10.5% compared to 6% in HIV-negative indivi-
duals (p = 0.002) (Table 2). A comparable rate of anti-
HCV marker was observed in HIV-infected individuals
with or without ART. HCV- RNA was detected in 6
(9.1%) of all 66 anti-HCV positive samples and viral
load ranged from 31 IU/ml - 4.294 million IU/ml of
serum. Rate of HCV- RNA was similar among anti-
HCV- positive participants with or without HIV infec-
tion (7.1% versus 12.5%, respectively; p = 0.39), and in
those HIV-infected with or without ART (5.3% versus
8.7%, respectively; p = 0.43).
The exposure of HIV-infected and HIV-non-infected
participants to different risk factors for HCV infection is
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summarised in Table 3. Histories of ear piercing and
tooth extraction were the most frequently reported
exposures in both HIV sero-groups. Among females
with HIV infection, 22.5% reported having ahistory of
abortion. Sero- prevalence rate of anti-HCV was higher
in HIV-infected participants who reported having multi-
ple sexual partners. There was no significant difference
in odds of HCV infection in participants with and with-
out HCV risk factors in either HIV sero-group (Table
3).
Discussion
The sero-prevalence of anti-HCV was 10.5% in HIV-
positive and 6% in HIV-negative individuals. None of
the risk factors included in the analysis significantly
increased the odds of HCV exposure. The rate of HIV-
HCV co-infection in the present study was higher com-
pared to findings in an earlier report which investigated
residents of Addis Ababa (4.5%) [7]. Although we found
a lower co-infection rate compared with developed
nations [9,10], the magnitude of HCV in Ethiopia would
become a concern as HIV is more prevalent in our
settings.
Despite a weak association, we found a significant dif-
ference in rates of anti-HCV positivity between HIV-
infected and HIV-non-infected individuals. In agree-
ment, a previous report showed that HIV positive inha-
bitants in Addis Ababa had about five-fold rate of anti-
HCV compared with HIV negative individuals [7]. How-
ever, associations between HCV and HIV infections in
our settings were not as strong as those reported from
industrialized countries where HIV can occur among
HCV infected people exclusively [10,11].
Unlike most western countries, risk factors such as
repeated transfusions, haemodialysis, or injection drug
use are very rare in Ethiopia where transmission of HIV
is primarily through heterosexual exposure [12]. While it
remains to be fully established, rising evidences point to
implications of sexual activity in HCV transmission [13].
Sexual transmission of HCV that might be facilitated by
HIV and other STIs has also been reported [14,15].
Therefore, the role of sexual transmission should not be
neglected as it may contribute to the higher rate of anti-
HCV among HIV-infected individuals.
In the current study, the odds of HCV infection were
not shown to be significantly affected by the exposure
status of participants to various medical practices. This
result contrasts with afinding from Egypt where risk fac-
tors including blood transfusion, invasive medical proce-
dures, and frequent injections significantly increased the
odds of HCV infection [16]. This may be due to the
strength of risk factors varying according to HCV epide-
miology in a given geographical area. Moreover, unlike a
report from Brazil [13], our investigation as well as a
previous study from Egypt [16] showed that the odds of
HCV infection was not significantly higher in
Table 1 Socio-demographic characteristics of HIV-positive








Rural 21 (5.3) 17 (4.2) 38(4.8)
Urban 379 (94.7) 383(95.8) 762(95.2)
Sex
Male 151(37.8) 191(47.8) 342 (42.8)
Female 249 (62.2) 209(52.2) 458 (57.2)
Age (years)
<20 6(12.5) 42(87.5) 48 (6)
20-29 164(40.5) 241(59.5) 405 (50.6)
30-39 161(63.6) 92(36.4) 253 (31.6)
40-49 55(75.3) 18(24.7) 73 (9.1)
≥50 14(66.7) 7(33.3) 21 (2.6)
Marital status
Married 192(48) 97(24.2) 289 (36.1)
Single 60(15) 274(68.5) 334 (41.8)
Divorced 60(15) 20(5.0) 80 (10 )
Widowed 88(22) 9(2.2) 97 (12.1)
Religion
Orthodox 250(62.5) 163(40.8) 413 (51.6)
Protestant 112(28.0) 199(49.8) 311 (38.9)
Muslim 31(7.8) 37(9.2) 68 (8.5)
Other 7(1.8) 1(0.2) 8(1.0)
Educational status Educational stat
Illiterate 57(14.2) 19(4.8) 76 (9.5)
Primary school 169(42.2) 72(18.0) 241 (30.1)
Secondary school 150(37.5) 139(34.8) 289 (36.1)
Diploma 16(4.0) 119(29.8) 135 (16.9)
Degree 8(2) 51(12.8) 59 (7.4)
Table 2 Distribution of anti-HCV and HCV-RNA in HIV-positive and HIV-negative individuals at Hawassa HIV testing
centers, 2008
HCV Marker Total tested Number (%) positive HIV-positive HIV-negative
On ART ART naives Total
Tested +ve (%) Tested +ve (%) Tested +ve (%) Tested +ve (%)
Anti-HCV 800 66 (8.2) 200 19 (9.5) 200 23 (11.5) 400 42 (10.5) 400 24 (6)
HCV-RNA 66 6 (9.1) 19 1 (5.3) 23 2 (8.7) 42 3 (7.1) 24 3 (12.5)
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Table 3 Anti-HCV positivity in relation to HCV risk factors in HIV-positive and HIV- negative individuals at Hawassa
HIV testing centers, 2008
Characteristics HIV-positive HIV-negative









No 300(75.0) 35(11.7) 1 342 (85.5) 21(6.1) 1
Yes 100(25.0) 7(7.0) 0.57(0.25-1.33) 58 (14.5) 3(5.2) .83(0.24-2.89)
Blood transfusion
No 388(97.0) 41(10.6) 1 398(99.5) 24(6.0)
Yes 12(3.0) 1(8.3) 0.77(0.10-6.11) 2(0.5) 0 -
Unsafe injection
No 375(93.8) 40(10.7) 1 384(96.0) 24(6.2)
Yes 25(6.2) 2(8.0) 0.73(0.17-3.20) 16(4.0) 0 -
Multiple sexual partners *
No 315(78.8) 31(9.8) 1 344(86.0) 18(5.2) 1
Yes 85(21.2) 11(12.9) 1.3(0.65-2.84) 56(14.0) 6(10.7) 2.1(0.82-5.74)
Sexual transmitted infections **
No 282(70.5) 26(9.2) 1 380(95.0) 23(6.1) 1
Yes 118(29.5) 16(13.6) 1.54(0.80-3.0) 20(5.0) 1(5.0) 0.82(0.11-6.38)
Tooth extraction
No 278(69.5) 27(9.7) 1 286(71.5) 18(6.3) 1
Yes 122(30.5) 15(12.3) 1.30(0.67-2.55) 114(28.5) 6(5.3) 0.83(0.32-2.14)
Catheterization
No 393(98.2) 41(10.4) 1 399(99.8) 24(6.0) -
Yes 7(1.8) 1(14.3) 1.43(0.17-12.18) 1(0.2) 0
Scarification
No 373(93.2) 39(10.5) 1 367(91.8) 23(6.3) 1
Yes 27(6.8) 3(11.1) 1.07(0.31-3.72) 33(8.2) 1(3.0) 0.47(0.06-3.58)
Abortion
No 193(77.5) 18(9.3) 1 195(93.3) 11(5.6) 1
Yes 56(22.5) 7(12.5) 1.39(0.55-3.51) 14(6.7) 1(7.1) 1.29(0.15-10.8)
Ear piercing
No 240(60.0) 22(9.2) 1 292(73.0) 16(5.5) 1
Yes 160(40.0) 20(12.5) 1.42(0.74-2.69) 108(27.0) 8(7.4) 1.38(0.57-3.32)
Surgery ***
No 376(94.0) 40(10.6) 1 388(97.0) 24(6.2)
Yes 24(6.0) 2(8.3) 0.76(0.17-3.37) 12(3.0) 0 -
Blood letting
No 390(97.5) 41(10.5) 1 398(99.5) 24(6.0)
Yes 10(2.5) 1(10.0) 0.95(0.12-7.66) 2(0.5) 0 -
Tattooing
No 365(91.2) 38(10.4) 1 376(94.0) 23(6.1) 1
Yes 35(8.8) 4(11.4) 1.11(0.37-3.32) 24(6.0) 1(4.2) 0.67(0.09-5.16)
History of liver disease ****
No 373(93.2) 41(11) 1 387(96.8) 23(5.9) 1
Yes 27(6.8) 1(3.7) 0.31(0.04-2.36) 13(3.2) 1(7.7) 1.32(0.16-10.6)
Contact with a person having liver disease
No 372(93.0) 39(10.5) 1 379(94.8) 24(6.3)
Yes 28(7.0) 3(10.7) 1.03(0.30-3.55) 21(5.2) 0 -
* having more than one sexual partner; ** have ever been diagnosed for sexual transmitted infections (excluding HIV); *** ever had minor or major surgical
operation; **** have ever been diagnosed for liver disease
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participants with tattoos or ear piercing compared with
those without the respective risk factors in either HIV
sero-groups.
HCV infection commonly takes achronic course and
studies have reported viraemia persisting in over 80% of
infected individuals [17,18]. In the present study, how-
ever, HCV-RNA was detected in 9.1% of anti-HCV posi-
tive individuals. Such a lower rate of HCV-RNA is
unusual and points to a need for further investigation in
our settings to confirm or challenge this finding. Factors
such as intact immune status [19] and heterosexual
HCV transmission [20] were suggested to contribute to
varying rates of spontaneous HCV clearance in different
geographical regions. In contrast, our study lacked
enough power to assess whether factors such as demo-
graphic characteristics, routes of transmission, HIV and
ART status were influencing rate of HCV clearance.
Findings in this study need to be interpreted in light of
its methodological limitations. First, lost participants,
who tested HIV positive at the centers and did not regis-
ter at the ART clinic, may introduce selection bias. Sec-
ond, there could be a survival bias as a result of deaths
occurring among patients with viral hepatic C within the
six months following the ART initiation. Third, lack of
confirming ELISA positive test results using an immuno-
blot test might lead to misinterpretation of anti-HCV
false positive results as HCV exposures.
In conclusion, HIV-infected individuals had signifi-
cantly higher positivity rate of anti-HCV although most
of them had no sign of viraemia. Hence, with priority
given for HIV- infected patients, testing those with anti-
HCV for HCV-RNA is important in order to manage
HIV-HCV co-infected patients appropriately. Further
studies on the epidemiology of HCV infection in our
settings are imperative to plan intervention methods
systematically.
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